Noven’s flagship product in the CNS/ADHD area is Daytrana® (methylphenidate transdermal system), the first and only transdermal system approved for ADHD in children ages 6-17. Daytrana® is marketed by Noven Therapeutics. Noven is developing an amphetamine transdermal system (ATS) for ADHD. If approved, ATS could complement Daytrana® and offer physicians and caregivers a new option in the management of ADHD.
Need Help Finding Daytrana®?
There is a shortage of all strengths of Daytrana® that is expected to last until third quarter of this year. The Pharmacy Locator Service (1-800-420-2719) may potentially identify a pharmacy that might have Daytrana® in stock. If you are unable to find a pharmacy that has Daytrana® in stock, please contact your health care provider.